Growth of tumors induced by Rous sarcoma virus (RSV) is controlled by alleles at the major histocompatibility complex locus in chickens, indicating that immunological host defense mechanisms play a major role. We show here that the resistance phenotype of CB regressor chickens can be partially reverted by treating the animals with a monoclonal antibody that neutralizes the major serotype of chicken type I interferon, ChIFN-␣. Injection of recombinant ChIFN-␣ into susceptible CC progressor chickens resulted in a dose-dependent inhibition of RSV-induced tumor development. This treatment was not effective, however, in CC chickens challenged with a DNA construct expressing the v-src oncogene, suggesting that the beneficial effect of type I interferon in this system resulted from its intrinsic antiviral activity and probably not from indirect immunmodulatory effects. By contrast, recombinant chicken interferon-␥ strongly inhibited tumor growth when given to CC chickens that were challenged with the v-src oncogene, indicating that the two cytokines target different steps of tumor development.
INTRODUCTION
The contribution of interferons (IFNs) to the regression of tumors is not well understood. Early results with crude preparations of type I IFN suggested formidable activity against various tumors in mice and humans (Strander, 1986; Gresser and Bourali, 1970) . However, systematic clinical studies with purified preparations of human IFN-␣ failed to confirm such activity against many important tumors, with the notable exception of several forms of leukemias in humans (for review see Ezaki, 1996) in which IFN-␣ therapy proved to be effective. Recombinant IFN-␥ exhibited antitumor activity in several experimental settings in mice (Fujiwara and Hamaoka, 1996; Sveinbjornsson et al., 1998; Xu et al., 1996; Mao et al., 1995) . However, a recent placebo-controlled clinical trial with recombinant human IFN-␥ failed to confirm antitumor activity of this cytokine in metastatic renal cell carcinoma (Gleave et al., 1998) . Collectively, these findings illustrate that the molecular basis of the antitumor activity of IFNs is currently not understood well enough.
A distinct feature of Rous sarcoma virus (RSV)
2 -induced tumors of chickens is that they are induced by a replication-competent retrovirus. Since IFNs are strong antiviral agents, one might assume that RSV-induced tumors should respond particularly well to IFN therapy. However, due to the fact that the genes for chicken IFNs have been cloned only recently (Sekellick et al., 1994; Schultz et al., 1995a,b; Sick et al., 1996; Digby and Lowenthal, 1995; Weining et al., 1996) , pure IFN preparations had previously not been available so that the role of these cytokines in the host defense against RSV-induced tumors could not be investigated. The CB (B 12 /B 12 ) and CC (B 4 /B 4 ) congenic lines of chickens have been studied extensively with respect to resistance to progressive growth of tumors induced by RSV (for review see Plachý et al., 1989 Plachý et al., , 1992 . When challenged with the Prague strain of RSV tumors rapidly develop in CC "progressor" chickens, whereas growth of RSV-induced tumors is strongly restricted in CB "regressor" chickens. Cloned LTR/v-src/LTR proviral DNA that codes for the v-src oncoprotein is also tumorigenic in chickens. The tumor growth restriction patterns in progressor and regressor chickens are similar irrespective of whether the sarcomas are induced by replication-competent RSV or by v-src proviral DNA, although the former tumors develop much faster in CC chickens (Svoboda et al., 1992) . The critical role of alleles at the major histocompatibility complex (B locus) in resistance against these tumors was formally proven by genetic experiments using appropriate backcross populations of chickens, suggesting that an immune-based mechanism of tumor regression is at work in this system (Plachý et al., 1994; Svoboda et al., 1996) . CC chickens are immunocompetent but their specific response to RSV antigens is low due to the lack of appropriate peptide motifs that would bind to the B 4 molecules. By contrast, the B 12 molecule encoded by the MHC allele of CB chickens can bind and present RSV peptides (Kaufman et al., 1995) .
We used a neutralizing monoclonal antibody to the major serotype of chicken type I IFN (ChIFN-␣) to investigate the role of this cytokine in the resistance of CB chickens toward RSV-induced disease. By treating disease-prone CC chickens with recombinant ChIFN-␣ and ChIFN-␥ we further evaluated the beneficial effects of these cytokines on the development of RSV-and v-src oncogene-induced tumors. Our results indicate that the prominent antitumor effect of ChIFN-␣ in this system is largely due to its potent antiviral activity. ChIFN-␥ seems to act by an independent mechanism, as it delayed the formation in CC chickens of v-src oncogene-induced tumors that were not responsive to ChIFN-␣ treatment.
RESULTS
Resistance of CB chickens to RSV-induced tumors is weakened by antibodies that neutralize ChIFN-␣ Infection of CB regressor chickens with RSV results in initial tumor growth that rapidly becomes restricted by the host immune response. Tumor size usually does not exceed 100 mm 2 in these animals at any time postinfection (Plachý et al., 1994) . Maximal tumor size is reached about 3 weeks after RSV challenge and the tumors disappear quickly thereafter. To evaluate the role of endogenous type I IFN in this resistance, we treated six CB chickens with monoclonal antibody 8A9 that selectively neutralizes ChIFN-␣, which represents the predominant serotype of virus-induced chicken IFN (Sick et al., 1998) . A control group of eight animals received equivalent amounts of irrelevant antibodies. Antibody therapy was started 3 days before RSV infection and was continued until 20 days postinfection. By this time all monoclonal antibody 8A9-treated animals had developed fairly large tumors with a mean size of about 240 mm 2 (Fig. 1) . The tumors of control antibody-treated animals were much smaller at this time point (mean size 105 mm 2 ) (Fig. 1) . The tumors of both groups of chickens regressed quickly during the following weeks. Since antibody administration was stopped on postchallenge day 20 due to shortage of purified protein, it remains unclear whether the beginning of tumor regression in the antibody-treated animals at this same time point was coincidential or whether it was due to rising IFN levels. Despite this obvious difficulty, the results of this experiment clearly indicated that endogenous IFN played a role in tumor growth restriction of CB chickens.
ChIFN-␣ inhibits the replication of RSV in cultured embryo fibroblasts from CB and CC chickens
The results of the above-described IFN depletion experiment did not distinguish between a direct antiviral effect of IFN on RSV replication and indirect inhibitory effects due to an immunostimulatory activity of this cytokine. We therefore measured whether ChIFN-␣ can inhibit the replication of our strain of RSV in cell culture. Experiments with cultures of secondary embryo cells from CB chickens clearly demonstrated that this was the case. IFN treatment of these cells reduced RSV titers about 25-fold (Fig. 2) . Interestingly, ChIFN-␣ exhibited a comparably potent antiviral effect toward RSV in cells from CC chickens (Fig. 2 ) that fail to restrict virus-induced tumor formation in vivo. Since it was unclear whether Escherichia coli-produced ChIFN-␣ was active in vivo, we performed a pilot experiment in which we measured whether intravenous injection of this material would result in enhanced expression of the IFN-inducible Mx gene. An adult chicken was given 10 6 IU/kg of purified ChIFN-␣ by the intravenous route. Blood was taken 8 h later and RNA was isolated from the PBMCs. RNA from PBMCs of an untreated chicken served as negative control. Northern blot analysis showed clearly detectable levels of Mx transcripts in the RNA sample from the IFN-treated animal but not in the sample from the untreated control animal (Fig. 3) , indicating that our preparation of ChIFN-␣ was also active in vivo.
To determine whether RSV-induced tumor development in CC chickens might be influenced by ChIFN-␣, we treated the chickens with a low-dose IFN regimen starting at 3 days prior to challenge with 100 focus-forming units (FFU) of RSV until day 30 postinfection. The animals received injections of 10 4 IU of ChIFN-␣ every second day. Tumor development was significantly delayed in IFN-treated animals compared to the untreated control chickens (Fig. 4A ). Maximal differences in the mean tumor sizes were observed between 35 and 42 days postinfection. IFN treatment also had a positive effect on the survival of the chickens. At 52 days postinfection, 10 of the 11 untreated chickens were dead. By contrast, all 9 IFN-treated animals were still alive at this time point (Fig. 4B) . Although the beneficial effect of the IFN therapy was clear-cut in this experiment, it failed to prevent lethal disease in the treated animals.
In a second experiment we evaluated whether increased doses of IFN would influence the results. For this experiment, we further lowered the virus challenge dose to 10 FFU per animal. Increasing the ChIFN-␣ dose from 10 4 to 10 5 or 10 6 IU per injection resulted in a dose-dependent reduction of the mean tumor size (Fig.  4C) . The mean survival time of the chickens was also affected positively. One of the eight animals that received 10 5 IU and two of the six animals that received 10 6 IU of ChIFN-␣ per injection survived until the termination of the experiment on day 120 postinfection (Fig. 4D) . By this time their tumors had disappeared.
ChIFN-␣ fails to inhibit tumor induction by the v-src oncogene in CC chickens
The therapeutic effect of IFN could have resulted from inhibition of RSV replication or could have been due to a stimulatory effect of IFN on the poorly performing immune system of CC chickens. If the latter effect was operative, the IFN therapy should be equally beneficial against tumors induced by either RSV or v-src DNA. We therefore challenged new groups of CC chickens with a DNA construct that codes for this viral oncogene product and subjected one group of eight animals to high-dose ChIFN-␣ therapy. No beneficial effect of the repeated injections of cytokine was observed under these experimental conditions. Actually, in this experiment the IFNtreated chickens developed slightly larger tumors than control animals (Fig. 5) . These results suggest that the antitumor effect of ChIFN-␣ in this system resulted from its potent antiviral activity rather than from immunomodulatory effects.
ChIFN-␥ inhibits v-src oncogene-induced tumor formation in CC chickens
Since ChIFN-␥ is a poor antiviral agent but a very potent activator of macrophages (Weining et al., 1996) , it was of interest to determine whether it might exhibit antitumor activity in vivo. We have previously shown that purified recombinant ChIFN-␥ is biologically active, whereas a variant protein lacking the C-terminal 18 amino acids is not (Puehler et al., 1998) . We therefore treated groups of eight CC progressor chickens with full-length or truncated forms of ChIFN-␥, while a control group received no treatment. Three days after the first injections, all animals were challenged with v-src DNA and tumor development was monitored. Figure 6 shows that tumor growth was very slow in chickens that were 6 IU/kg of ChIFN-␣ (ϩ), while a control animal was left untreated (Ϫ). Eight hours later, blood was taken from both animals, RNA was isolated from PBMCs and analyzed for the presence of transcripts derived from the Mx gene by Northern blotting. Reprobing of the membrane with radiolabeled chicken actin cDNA confirmed that equal amounts of RNA were loaded into the two lanes. FIG. 2 . Inhibition of RSV replication by ChIFN-␣ in cultured chicken embryo fibroblasts of CC and CB chickens. Monolayers of cells from CC and CB chickens were treated with 100 IU/ml of ChIFN-␣ or plain medium before infection with RSV at a multiplicity of 0.1 FFU. Three days later, the viral titers in the supernatants were determined. treated with full-length ChIFN-␥ and that the mean tumor size did not exceed 66 mm 2 during the complete observation period of 85 days. By contrast, in chickens treated with inactive mutant ChIFN-␥ tumors developed nearly as quickly as in the untreated control animals, and they reached sizes of 200 mm 2 or more within about 7 weeks.
We controlled for the remote possibility that the LTR, v-src, LTR construct had formed tumors because it was packaged by an endogenous retrovirus by performing Southern blot analysis of DNA samples from several tumors. This analysis yielded no evidence for the presence of avian leukemia virus and no evidence for v-src oncogene amplification or rearrangements (data not shown). Thus, unlike ChIFN-␣, recombinant ChIFN-␥ exhibited antitumor activity that cannot be simply due to inhibition of virus replication.
DISCUSSION
Previous genetic analyses had shown that the robust resistance of CB chickens to RSV-induced tumors results from a strong immunological response of these animals against the v-src oncogene and that the B 12 allele at the MHC locus is of critical importance in this defense process (Plachý et al., 1994; Svoboda et al., 1996) . It remained unclear, however, whether IFNs and other factors of the innate immune system also played a role. By injecting a monoclonal antibody that neutralizes ChIFN-␣ into RSV-infected CB chickens we obtained clear evidence that this cytokine contributes to the tumor resistance phenotype: in treated animals the initial growth of RSV-induced tumors was much more rapid than in control chickens that received irrelevant antibodies. A priori we could not distinguish between the possibility that the detrimental effect of the neutralization of virus-induced IFN-␣ was due to enhanced replication of RSV in the antibody-treated animals and the possibility that the immune system of the IFN-␣-depleted animals was compromised and failed to mount a quick and effective antitumor response. If the former possibility was correct, IFN-␣ should block RSV replication in cell culture and it should also have a beneficial effect when applied to CC chickens that cannot control RSV-induced tumors sufficiently well by immunological means. In agreement with these predictions we found that the infection of chicken embryo cells from CB and CC chickens was impaired to similar degrees when the cultures were treated with ChIFN-␣ and that treatment of RSV-infected CC chickens with recombinant ChIFN-␣ strongly delayed tumor growth and resulted in prolonged survival of the treated animals. If the second possibility was correct and if ChIFN-␣ indeed acted against RSV-induced tumors via a nonspecific stimulation of the immune system, it would be expected that ChIFN-␣ is also effective against experimental tumors induced by the isolated v-src oncogene. Contrary to this prediction we found that tumors resulting from injection of RSV DNA could not be treated successfully with ChIFN-␣. Taken together these results strongly suggested that the antitumor effect of ChIFN-␣ in this system resulted mostly if not exclusively from its antiviral activity. In sharp contrast to the results with ChIFN-␣, we found that ChIFN-␥ was active against tumors of CC chickens that were induced by the v-src oncogene. Thus, the antitumor activities of the two types of IFN appeared to be complementary in this system.
A picture thus emerges that shows that there are at least two lines of defense against RSV-induced tumors in chickens. The first line of defense is based on virusinduced IFN, which may be critical at an early stage after infection and which may limit virus spread before the second line of defense, the specific immune response against the intruder, is generated. In chickens of strains CC and CB the first line of defense appears to be in place but the physiological levels of virus-induced IFN probably cannot block RSV replication well enough to prevent tumor growth and disease in CC chickens that fail to mount an effective immune response against RSV. As predicted in this model, we found that when the first line of defense was enhanced by supplying large amounts of recombinant ChIFN-␣, we could delay tumor growth rather effectively in CC chickens. The complementary experiment also worked: when the first line of defense was weakened by neutralizing virus-induced IFN by monoclonal antibody 8A9 in CB chickens, it took these animals longer to get the growing tumor under control. The second line of defense is well developed in CB chickens that carry the B 12 allele at the MHC locus, whereas it is very weak in CC chickens that carry the B 4 allele. Our successful inhibition of v-src oncogene-induced tumor growth in CC chickens with recombinant ChIFN-␥ indicates that the poor immunological defense of these animals can be strengthened by this cytokine. The presumably complex immunological mechanisms behind the observed enhanced performance of IFN-␥-treated CC chickens remain to be elucidated.
Considering the fact that IFN-␣ is fairly effective against several tumors in humans (Strander, 1986; Ezaki, 1996) and the fact that clinical trials with IFN-␥ yielded disappointing results (Gleave et al., 1998) , our findings with v-src oncogene-induced tumors in chickens that revealed exclusive therapeutic effects of IFN-␥ came as a surprise. Our findings are in agreement, however, with results of experiments in mice that lack a functional type I IFN system that suggested that the physiological role of IFN-␣ is restricted to antiviral defense (Müller et al., 1994) . From these observations it appears that the most spectacular therapeutic effects of IFN-␣ might be observed in clinical settings that involve virus-induced tumors.
MATERIALS AND METHODS

Animals
Chickens of the Prague congenic lines CB (B 12 /B 12 ) and CC (B 4 /B 4 ) were used (Plachý et al., 1989 . Both congenic lines were free of avian leukosis virus. 
RSV titrations
The Prague strain of RSV subgroup C (PR-RSV-C) was used. Virus titers were measured by the focus assay, in which chicken fibroblasts were pretreated for 1 h with 10 g of polybrene per 4 ml of medium (Toyoshima and Vogt, 1969) and expressed as FFU/ml.
Challenge of chickens with RSV and tumor monitoring
Approximately 10-week-old chickens were inoculated subcutaneously into the left wing webs with 0.1 ml of stock virus (usually 100 FFU) diluted in Eagle's minimal essential medium containing 5% calf serum, 5% fetal bovine serum, 10% tryptose phosphate broth, 100 IU/ml of penicillin, and 100 g/ml of streptomycin. The area of tumor growth in the wing web was measured by placing transparent foil on the tumor and tracing its contours. The picture of the tumor was then transferred onto a sheet of millimeter paper. The tumor size was calculated as half the sum of outer and inner regular figures fitting the picture of the tumor (Svoboda et al., 1992) .
Preparation and inoculation of v-src proviral DNA
The LTR/v-src/LTR provirus used here was originally rescued from H-19 hamster tumor cells and transfected into Japanese quail cells (Geryk et al., 1986) . The clonal line F6K4 of transformed quail cells was used for DNA cloning. The proviral DNA in this cell line has lost its replication competence due to a deletion of all viral genes except v-src (Bodor and Svoboda, 1989) . The viral DNA was released with BamHI and HindIII from lambda F6K4c1.2 (Svoboda et al., 1992) and cloned into the same restriction sites of pUC18. Maxipreps of plasmid DNA were prepared by the alkaline lysis method and supercoiled DNA was purified twice on CsCI gradients. This DNA was linearized again by BamHI and HindIII double digestion, aliquoted (150 g/ml) in TE buffer (10 mM Tris, 1 mM EDTA pH 8.0), and kept at Ϫ20°C. For each DNA inoculation a fresh aliquot was used. About 1.5 g of DNA diluted in phosphate-buffered saline (total volume 100 l) was inoculated subcutaneously into the left wing web, an amount that corresponds to about 0.6 g of the LTR/v-src/LTR DNA fragment.
Recombinant ChIFNs
The production in E. coli and purification to near homogeneity of recombinant ChIFN-␣ (previously referred to as ChIFN1 (Sick et al., 1998) ) have been described (Schultz et al., 1995b) . Purified ChIFN-␣ had a specific activity of 2 ϫ 10 7 IU/mg. Histidine-tagged recombinant ChIFN-␥ (His-ChIFN-␥) was produced in E. coli and purified as described (Weining et al., 1996) . A biologically inactive mutant form of His-ChIFN-␥ that lacks the 18 C-terminal amino acids (Puehler et al., 1998) served as negative control.
ChIFN-␣-specific monoclonal antibody 8A9
Monoclonal antibodies were developed by immunizing Lou/c rats with recombinant ChIFN-␣. Hybridomas were selected for their ability to neutralize the antiviral activity of ChIFN-␣ in cytopathic effect reduction assays. A single monoclonal antibody (8A9, rat IgG1 subclass) neutralized the major serotype of chicken type I IFN (ChIFN-␣, previously designated ChIFN1 (Sick et al., 1998) ) but not the minor serotype (ChIFN-␤, previously designated ChIFN2 (Sick et al., 1998) ) (data not shown). The monoclonal antibody was purified from cell culture supernatants by affinity chromatography on protein G-Sepharose, followed by dialysis against PBS. Antibody preparations were adjusted to a final concentration of 1 mg/ml.
Treatment of chickens with monoclonal antibody 8A9
CB chickens were inoculated intravenously with 50 g of purified monoclonal antibody 8A9 starting 3 days before challenge with RSV, and nine consecutive injections of the same antibody dose were given in 1-to 3-day intervals thereafter. The last injection was given 20 days postchallenge. Control chickens received 50 l of normal rabbit serum by the same regimen.
IFN treatment
CC chickens were treated with recombinant ChIFN-␣ by injecting 10 4 , 10 5 , or 10 6 IU by the intravenous route. This treatment was started 3 days before challenge with RSV or v-src DNA. Altogether 20 injections were given in 1-to 2-day intervals up to the 30th day postchallenge. Ten-microgram samples of full-length or C-terminally truncated His-ChIFN-␥ were injected intravenously. The first two injections were given 3 days and 6 h before tumor challenge. Altogether 19 injections were given in 2-to 4-day intervals. The last injection was on day 53.
Assay for measuring the expression of the IFNinducible Mx gene in vivo
A single dose of 10 6 IU/kg of ChIFN-␣ was administered intravenously to an adult chicken. A control animal was left untreated. Eight hours later, blood was collected, RNA was prepared from the PBMCs, and samples were assayed by Northern blotting for transcripts of the IFNinducible Mx gene using a radiolabeled cDNA probe (Bernasconi et al., 1995) . To confirm that similar amounts of RNA were loaded into each lane, the blot was reprobed with a radiolabeled actin cDNA probe (Kost et al., 1983) .
Cell culture assay for RSV replication inhibition
Secondary chicken embryo fibroblasts were treated with 100 IU/ml of ChIFN-␣ for 18 h before infection with PR-RSV-C at a multiplicity of 0.1 FFU. The same concen-tration of ChIFN-␣ was present in the medium after the cells had been infected. Three days after infection, the virus yields in the supernatants were determined by a focus-forming assay as described (Svoboda et al., 1985) .
